Changes in aqueous and vitreous inflammatory cytokine levels in neovascular age-related macular degeneration: a systematic review and meta-analysis.
age-related macular degeneration
cytokines
meta-analysis
ocular biomarkers
Journal
Acta ophthalmologica
ISSN: 1755-3768
Titre abrégé: Acta Ophthalmol
Pays: England
ID NLM: 101468102
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
22
02
2020
revised:
30
05
2020
accepted:
04
06
2020
pubmed:
1
7
2020
medline:
23
9
2021
entrez:
1
7
2020
Statut:
ppublish
Résumé
Inflammatory cytokines are involved in the pathogenesis of neovascular age-related macular degeneration (nAMD) and have been shown to be useful as diagnostic and predictive biomarkers. Given the heterogeneity of data within the literature, we aimed to quantitatively summarize data related to inflammatory cytokines in nAMD. A systematic search without year limitation was performed up to 13 April 2020. Studies were included if they provided data on aqueous or vitreous cytokine concentrations in patients with nAMD. Data were extracted from 95 studies that encompassed 3105 study eyes with nAMD and 1209 control eyes. Effect sizes were generated as standardized mean differences (SMDs) of cytokine concentrations between patients with nAMD and controls. Among the 4314 eyes in 95 studies, aqueous concentrations (standard mean difference, 95% confidence interval and p-value) of MCP-1 (0.43, 0.09 to 0.77 and p = 0.01), MIG (0.63, 0.31 to 0.94 and p = 0.0001), TGF-β (0.45, 0.07 to 0.82 and p = 0.02) and VEGF (0.64, 0.31 to 0.98 and p = 0.0001) were significantly higher in patients with nAMD compared to healthy controls. No differences, failed sensitivity analyses or insufficient data were found between patients with nAMD and healthy controls for the concentrations of the remaining cytokines and with all vitreous samples. Previous studies had shown conflicting associations with nAMD for all 27 cytokines assessed. Our analysis indicates multiple candidate cytokines other than VEGF that are implicated in nAMD and adds clarity to the previous literature. This will help focus translational research in nAMD investigating biomarkers and therapeutic targets.
Substances chimiques
Biomarkers
0
Cytokines
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
134-155Informations de copyright
© 2020 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.
Références
Absar SF, Cyr D, Proia AD et al. (2012): Identifying the roles of interferon-gamma inducible chemokines in progression of Age-Related Macular Degeneration (AMD). Invest Ophthalmol Vis Sci 53: 376-6489.
Agawa T, Usui Y, Wakabayashi Y et al. (2014): Profile of intraocular immune mediators in patients with age-related macular degeneration and the effect of intravitreal bevacizumab injection. Retina 34: 1811-1818.
Agrawal R, Balne PK, Wei X et al. (2019): Cytokine profiling in patients with exudative age-related macular degeneration and polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci 60: 376-382.
Ahn JK & Moon HJ (2009): Changes in aqueous vascular endothelial growth factor and pigment epithelium-derived factor after ranibizumab alone or combined with verteporfin for exudative age-related macular degeneration. Am J Ophthalmol 148: 718-724.e1.
Aiello LP, Avery RL, Arrigg PG et al. (1994): Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331: 1480-1487.
Baba T, Bikbova G, Kitahashi M, Yokouchi H, Oshitari T & Yamamoto S (2014): Level of vascular endothelial growth factor 165b in human aqueous humor. Curr Eye Res 39: 830-836.
Bai Y, Liang S, Yu W, Zhao M, Huang L, Zhao M & Li X (2014): Semaphorin 3A blocks the formation of pathologic choroidal neovascularization induced by transforming growth factor beta. Mol Vis 20: 1258-1270.
ten Berge JC, Fazil Z, van den Born I, Wolfs RCW, Schreurs MWJ, Dik WA & Rothova A (2019): Intraocular cytokine profile and autoimmune reactions in retinitis pigmentosa, age-related macular degeneration, glaucoma and cataract. Acta Ophthalmol 97: 185-192.
Bhutto IA, McLeod DS, Hasegawa T, Kim SY, Merges C, Tong P & Lutty GA (2006): Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Exp Eye Res 82: 99-110.
Bressler NM, Bressler SB & Fine SL (1988): Age-related macular degeneration. Surv Ophthalmol 32: 375-413.
Cabral T, Polido J, Okuda EA, Oshima A, Serracarbassa P, Belfort R & Regatieri CV (2015): VEGF dosage curve in the aqueous humor after bevacizumab intravitreal injection in patients with neovascular AMD. Invest Ophthalmol Vis Sci 56: 1513.
Cabral T, Lima LH, Polido J, Correia EP, Serracarbassa PD, Regatieri CV & Rubens B (2016): Angiogenesis agents levels after bevacizumab intravitreal injection in patients with neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 57: 3341.
Cabral T, Lima LH, Mello LGM et al. (2018): Bevacizumab injection in patients with neovascular age-related macular degeneration increases angiogenic biomarkers. Ophthalmol Retina 2: 31-37.
Cacciamani A, Parravano M, Scarinci F, Esposito G, Varano M & Micera A (2016): A simple spontaneous vitreal reflux collecting procedure during intravitreal injection: set-up and validation studies. Curr Eye Res 41: 971-976.
Campochiaro PA, Choy DF, Do DV, Hafiz G, Shah SM, Nguyen QD, Rubio R & Arron JR (2009): Monitoring ocular drug therapy by analysis of aqueous samples. Ophthalmology 116: 2158-2164.
Campochiaro PA, Lauer AK, Sohn EH et al. (2017): Lentiviral vector gene transfer of endostatin/angiostatin for macular degeneration (GEM) study. Hum Gene Ther 28: 99-111.
Celik N, Scheuerle A, Auffarth GU, Kopitz J & Dithmar S (2015): Intraocular pharmacokinetics of aflibercept and vascular endothelial growth factor-A. Invest Ophthalmol Vis Sci 56: 5574-5578.
Cha DM, Woo SJ, Kim H-J, Lee C & Park KH (2013): Comparative analysis of aqueous humor cytokine levels between patients with exudative age-related macular degeneration and normal controls. Invest Ophthalmol Vis Sci 54: 7038-7044.
Chalam KV, Grover S, Sambhav K, Balaiya S & Murthy RK (2014): Aqueous interleukin-6 levels are superior to vascular endothelial growth factor in predicting therapeutic response to bevacizumab in age-related macular degeneration. J Ophthalmol 2014: 502174.
Chan W-M, Lai TYY, Chan K-P, Li H, Liu DTL, Lam DSC & Pang CP (2008): Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia. Retina 28: 1308-1313.
Cho Y, Cao X, Shen D, Tuo J, Parver LM, Rickles FR & Chan CC (2011): Evidence for enhanced tissue factor expression in age-related macular degeneration. Lab Invest 91: 519-526.
Clemons TE, Milton RC, Klein R, Seddon JM & Ferris FL & Age-Related Eye Disease Study Research Group (2005): Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. Ophthalmology 112: 533-539.
dell'Omo R, Cassetta M, dell'Omo E, di Salvatore A, Hughes JM, Aceto F, Porcellini A & Costagliola C (2012): Aqueous humor levels of vascular endothelial growth factor before and after intravitreal bevacizumab in type 3 versus type 1 and 2 neovascularization. A prospective, case-control study. Am J Ophthalmol 153: 155-161.e2.
Ecker SM, Pfahler SM, Hines JC, Lovelace AS & Glaser BM (2012): Sequential in-office vitreous aspirates demonstrate vitreous matrix metalloproteinase 9 levels correlate with the amount of subretinal fluid in eyes with wet age-related macular degeneration. Mol Vis 18: 1658-1667.
Ecker SM, Poulsen TM, Hines JC & Glaser BM (2014): Changes in the vitreous proteome one month following initial anti-VEGF treatment for wet amd correlate with treatment response. Invest Ophthalmol Vis Sci 55: 570.
Essex RW, Nguyen V, Walton R et al. (2016): Treatment patterns and visual outcomes during the maintenance phase of treat-and-extend therapy for age-related macular degeneration. Ophthalmology 123: 2393-2400.
Fauser S & Muether PS (2016): Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times. Br J Ophthalmol 100: 1494-1498.
Fauser S, Schwabecker V & Muether PS (2014): Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration. Am J Ophthalmol 158: 532-536.
Fauser S, Viebahn U & Muether PS (2015): Intraocular and systemic inflammation-related cytokines during one year of ranibizumab treatment for neovascular age-related macular degeneration. Acta Ophthalmol 93: 734-738.
Fayzrakhmanov R & Bokbov M& Shevchuk N (2015): Cytokine profile of aqueous humour of anterior chamber in patients with age-related macular degeneration. EURETINA Abstract.
Feng J, Chen L, Yuan M, Pan C & Jiang Y (2018): Aqueous humor levels of cytokines in polypoidal choroidal vasculopathy and age-related macular degeneration. Int J Clin Exp Med 11: 7270-7278.
Ferris FL, Fine SL & Hyman L (1984): Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 102: 1640-1642.
Fiedler U, Reiss Y, Scharpfenecker M et al. (2006): Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 12: 235-239.
Food and Drug Administration (2018): Bioanalytical method validation guidance for industry (agency docket number FDA-2013-D-1020). Washington, DC: U.S. Government Printing Office.
Friedman DS, O'Colmain BJ, Muñoz B et al. (2004): Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122: 564-572.
Funatsu H, Yamashita H, Noma H et al. (2005): Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefes Arch Clin Exp Ophthalmol 243: 3-8.
Ghosh A, Chevour P, Krishna SG, Sinha S, Sinha D & Sethu S (2017): Elevated Angiogenin levels associated with both forms of age-related macular degeneration is regulated by hypoxia and telomerase. Invest Ophthalmol Vis Sci 58: 811.
Glaser BM, Poulsen TM, Hines JC & Ecker SM (2014): The difference in response after 3 months of anti-VEGF in wet AMD correlates with differences in vitreous protein biomarkers. Invest Ophthalmol Vis Sci 55: 568.
Hata M, Oishi A, Yamashiro K et al. (2017): I Incidence and causes of vision loss during aflibercept treatment for neovascular age-related macular degeneration: One-year follow-up. Retina 37: 1320-1328.
Hayden JA, van der Windt DA, Cartwright JL, Côté P & Bombardier C (2013): Assessing bias in studies of prognostic factors. Ann Intern Med 158: 280-286.
Hines JC, Poulsen TM, Ecker SM & Glaser BM (2014): long-term differences in the vitreous proteome of wet amd anti-vegf responders versus non-responders during 12 months of treatment. Invest Ophthalmol Vis Sci 55: 569.
Holekamp NM, Bouck N & Volpert O (2002): Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration. Am J Ophthalmol 134: 220-227.
Hsu M-Y, Hung Y-C, Hwang D-K et al. (2016): Detection of aqueous VEGF concentrations before and after intravitreal injection of anti-VEGF antibody using low-volume sampling paper-based ELISA. Sci Rep 6: 34631.
Huber M & Wachtlin J (2012): Vitreous levels of proteins implicated in angiogenesis are modulated in patients with retinal or choroidal neovascularization. Ophthalmologica 228: 188-193.
Jonas JB & Neumaier M (2007a): Erythropoietin levels in aqueous humour in eyes with exudative age-related macular degeneration and diabetic retinopathy. Clin Exp Ophthalmol 35: 186-187.
Jonas JB & Neumaier M (2007b): Vascular endothelial growth factor and basic fibroblast growth factor in exudative age-related macular degeneration and diffuse diabetic macular edema. Ophthalmic Res 39: 139-142.
Jonas JB, Tao Y, Neumaier M & Findeisen P (2010): Monocyte chemoattractant protein 1, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1 in exudative age-related macular degeneration. Arch Ophthalmol 128: 1281-1286.
Jonas JB, Tao Y, Neumaier M & Findeisen P (2012): Cytokine concentration in aqueous humour of eyes with exudative age-related macular degeneration. Acta Ophthalmol 90: e381-8.
Jonas JB, Wang YX, Xu L & Wei WB (2018): Age-related macular degeneration in China: a population-based and clinical study. The Lancet 392: S86.
Kato Y, Sekiryu T, Oguchi Y, Omori T, Machida T & Sekine H (2019): Complement activation product levels in aqueous humor of patients with age-related macular degeneration. Invest Ophthalmol Vis Sci 60: 777.
Kersten E, Paun CC, Schellevis RL et al. (2018): Systemic and ocular fluid compounds as potential biomarkers in age-related macular degeneration. Surv Ophthalmol 63: 9-39.
Kim TW, Kang JW, Ahn J et al. (2012): Proteomic analysis of the aqueous humor in Age-related Macular Degeneration (AMD) Patients. J Proteome Res 11: 4034-4043.
Kim JH, Shin JP, Kim IT & Park DH (2018): Angiopoietin-like 4 correlates with response to intravitreal Ranibizumab injections in neovascular age-related macular degeneration. Retina 38: 523-530.
Klein R, Klein BE & Linton KL (1992): Prevalence of age-related maculopathy. The Beaver Dam Eye Study.Ophthalmology 99: 933-943.
Kramer M, Hasanreisoglu M, Feldman A et al. (2012): Monocyte chemoattractant protein-1 in the aqueous humour of patients with age-related macular degeneration. Clin Exp Ophthalmol 40: 617-625.
Kreissig I, Jonas JB, Tao Y, Neumaier M & Findeisen P (2010): Monocyte chemoattractant protein-1 concentration in aqueous humour of eyes with exudative age-related macular degeneration. Invest Ophthalmol Vis Sci 51: 3325.
Krishna Gadde SGKG, Chevour P, Sinha S, Shetty R, Sethu S & Ghosh A (2017): Altered levels of aqueous humour soluble factors are associated with therapy-mediated resolution of macular edema in patients with Choroidal Neovascular Membranes. Invest Ophthalmol Vis Sci 58: 2305.
Kuiper JJW, Beretta L, Nierkens S et al. (2017): An ocular protein triad can classify four complex retinal diseases. Sci Rep 7: 41595.
Liu F, Ding X, Yang Y et al. (2016): Aqueous humor cytokine profiling in patients with wet AMD. Mol Vis 22: 352-361.
Madhusudhana KC, Lee AY, Keane PA et al. (2016): UK neovascular age-related macular degeneration database. Report 6: time to retreatment after a pause in therapy. Outcomes from 92 976 intravitreal ranibizumab injections. Br J Ophthalmol 100: 1617-1622.
Manresa N, Mulero J, Losada M & Zafrilla P (2015): Effect of pegaptanib and ranibizumab on plasma and vitreous homocysteine in patients with exudative age- related macular degeneration. Retina 35: 1765-1771.
Meacock WR, Spalton DJ & Stanford MR (2000): Role of cytokines in the pathogenesis of posterior capsule opacification. Br J Ophthalmol 84: 332-336.
Mehrad B, Keane MP & Strieter RM (2007): Chemokines as mediators of angiogenesis. Thromb Haemost 97: 755-762.
Mesquita J, Castro-de-Sousa JP, Vaz-Pereira S, Neves A, Passarinha LA & Tomaz CT (2018): Evaluation of the growth factors VEGF-a and VEGF-B in the vitreous and serum of patients with macular and retinal vascular diseases. Growth Factors 36: 48-57.
Miao H, Tao Y & Li X-X (2012): Inflammatory cytokines in aqueous humor of patients with choroidal neovascularization. Mol Vis 18: 574-580.
Mimura T, Funatsu H, Noma H et al. (2019): Aqueous Humor Levels of Cytokines in Patients with Age-Related Macular Degeneration. Ophthalmologica 241: 81-89.
Minaker SA, Mason RH, Bamakrid M, Lee Y & Muni RH (2019): Changes in aqueous and vitreous inflammatory cytokine levels in retinal vein occlusion: a systematic review and meta-analysis. J VitreoRetinal Dis 4: 36-64.
Moher D, Liberati A, Tetzlaff J & Altman DG & PRISMA Group (2009): Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 6: e1000097.
Motohashi R, Noma H, Yasuda K, Kotake O, Goto H & Shimura M (2017): Dynamics of inflammatory factors in aqueous humor during ranibizumab or aflibercept treatment for age-related macular degeneration. Ophthalmic Res 58: 209-216.
Motohashi R, Noma H, Yasuda K, Kotake O, Goto H & Shimura M (2018a): Dynamics of soluble vascular endothelial growth factor receptors and their ligands in aqueous humour during ranibizumab for age-related macular degeneration. J Inflamm 15: 26.
Motohashi R, Noma H, Yasuda K, Kotake O, Goto H & Shimura M (2018b): Dynamics of inflammatory factors in aqueous humor under Ranibizumab or Aflibercept treatment for age-related macular degeneration. Invest Ophthalmol Vis Sci 59: 62.
Muether PS, Hermann MM, Viebahn U, Kirchhof B & Fauser S (2012): Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab. Ophthalmology 119: 2082-2086.
Muether PS, Neuhann I, Buhl C, Hermann MM, Kirchhof B & Fauser S (2013a): Intraocular growth factors and cytokines in patients with dry and neovascular age-related macular degeneration. Retina 33: 1809-1814.
Muether PS, Hermann MM, Dröge K, Kirchhof B & Fauser S (2013b): Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration. Am J Ophthalmol 156: 989-993.e2.
Nagaraj S, Chevour P, Sethu S, Gadde SGK & Ghosh A (2016): June 15): Soluble molecular mediators associated with Choroidal Neovascular Membranes (CNVM) in patient aqueous humor. Invest Ophthalmol Vis Sci 57: 5804.
Ng DS, Yip YW, Bakthavatsalam M, Chen LJ, Ng TK, Lai TY, Pang CP & Brelén ME (2017): Elevated angiopoietin 2 in aqueous of patients with neovascular age related macular degeneration correlates with disease severity at presentation. Sci Rep 7: 45081.
Nielsen MK, Subhi Y, Molbech CR, Nilsson LL, Nissen MH & Sørensen TL (2019): Imbalances in tissue inhibitors of metalloproteinases differentiate choroidal neovascularization from geographic atrophy. Acta Ophthalmol 97: 84-90.
Nogoceke E, Duran-Pacheco G, Widmer G, Piraino P, Koss M & Hartmann G (2016): June 15): Levels of vitreous angiopoietin-2 are associated with vitreous levels of inflammatory cytokines in patients with age-related macular degeneration or diabetic retinopathy. Invest Ophthalmol Vis Sci 57: 4813.
Nomura Y, Takahashi H, Tan X, Fujino Y, Kawashima H & Yanagi Y (2016): Effect of posterior vitreous detachment on aqueous humor level of vascular endothelial growth factor in exudative age-related macular degeneration patients. Graefes Arch Clin Exp Ophthalmol 254: 53-57.
Park DH, Kim JH, Shin JP & Kim IT (2017): Angiopoietin-like 4 correlates with response to intravitreal ranibizumab injections in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 58: 2332.
Pongsachareonnont P, Lam WC & Mak MYK (2017): Intraocular cytokines in neovascular age-related macular degeneration non-responder to ranibizumab treatment. Invest Ophthalmol Vis Sci 58: 3205.
Pongsachareonnont P, Mak MYK, Hurst CP & Lam WC (2018): Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment. Clin Ophthalmol 12: 1877-1885.
Qin X-Y, Zhang S-P, Cao C, Loh YP & Cheng Y (2016): Aberrations in peripheral inflammatory cytokine levels in Parkinson disease. JAMA Neurol 73: 1316-9.
Regula JT, Lundh von Leithner P, Foxton R et al. (2016): Targeting key angiogenic pathways with a bispecific Cross MAb optimized for neovascular eye diseases. EMBO Mol Med 8: 1265-1288.
Rezar-Dreindl S, Sacu S, Eibenberger K et al. (2016): The intraocular cytokine profile and therapeutic response in persistent neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 57: 4144-4150.
Rezende FA, Lapalme E, Qian CX, Smith LE, SanGiovanni JP & Sapieha P (2014): Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration. Am J Ophthalmol 158: 1071-1078.
Roh MI, Kim HS, Song JH, Lim JB, Koh HJ & Kwon OW (2009): Concentration of cytokines in the aqueous humor of patients with naive, recurrent and regressed CNV associated with amd after bevacizumab treatment. Retina 29: 523-529.
Roh MI, Lim SJ, Ahn JM, Lim JB & Kwon OW (2010): Concentration of cytokines in age-related macular degeneration after consecutive intravitreal bevacizumab injection. Graefes Arch Clin Exp Ophthalmol 248: 635-640.
Sakamoto S, Takahashi H, Tan X et al. (2018): Changes in multiple cytokine concentrations in the aqueous humour of neovascular age-related macular degeneration after 2 months of ranibizumab therapy. Br J Ophthalmol 102: 448-454.
Sakurada Y, Nakamura Y, Yoneyama S et al. (2015): Aqueous humor cytokine levels in patients with polypoidal choroidal vasculopathy and neovascular age-related macular degeneration. Ophthalmic Res 53: 2-7.
Sato T, Takeuchi M, Karasawa Y, Ito M & Enoki T (2015): Elevated levels of helper T cell-related cytokines in the aqueous humor in age-related macular degeneration and retinal vein occlusion. Invest Ophthalmol Vis Sci 56: 847.
Sato T, Takeuchi M, Karasawa Y, Enoki T & Ito M (2018a): Intraocular inflammatory cytokines in patients with neovascular age-related macular degeneration before and after initiation of intravitreal injection of anti-VEGF inhibitor. Sci Rep 8: 1098.
Sato T, Takeuchi M, Karasawa Y, Ito M & Enoki T (2018b): Cytokine profiles of aqueous humor in patients with neovascular age-related macular degeneration by cluster analysis. Invest Ophthalmol Vis Sci 59: 5554.
Sato T, Takeuchi M, Karasawa Y, Takayama K & Enoki T (2019a): Comprehensive expression patterns of inflammatory cytokines in aqueous humor of patients with neovascular age-related macular degeneration. Sci Rep 9: 19447.
Sato T, Takeuchi M, Karasawa Y, Tanaka A & Enoki T (2019b): Changes of cytokine patterns in the aqueous humor of neovascular age- related macular degeneration after 2 months of aflibercept treatment. Invest Ophthalmol Vis Sci 60: 776.
Saunders DJ, Muether PS & Fauser S (2015): A model of the ocular pharmacokinetics involved in the therapy of neovascular age-related macular degeneration with ranibizumab. Br J Ophthalmol 99: 1554-1559.
Sawada O, Miyake T, Kakinoki M, Sawada T, Kawamura H & Ohji M (2010): Aqueous vascular endothelial growth factor after intravitreal injection of pegaptanib or ranibizumab in patients with age-related macular degeneration. Retina 30: 1034-1038.
Sawada T, Wang X, Sawada O, Saishin Y & Ohji M (2018): Aqueous vascular endothelial growth factor and aflibercept concentrations after bimonthly intravitreal injections of aflibercept for age-related macular degeneration. Clin Exp Ophthalmol 46: 46-53.
Schori C, Trachsel C, Grossmann J, Zygoula I, Barthelmes D & Grimm C (2018): The proteomic landscape in the vitreous of patients with age-related and diabetic retinal disease. Invest Ophthalmol Vis Sci 59: 31-40.
Shchuko AG, Zaytseva NV & Zlobin IV (2014): Intraocular cytokines concentrations in patients with different levels of activity of retinal pathologies. Ophthalmologica 232: 1-98.
Sitnilska V, Altay L, Enders P, Hermann M, Muether PS & Fauser S (2019): Onset of retinal pigment epithelium atrophy subsequent to anti-VEGF Therapy in patients with neovascular age-related macular degeneration. Ophthalmologica 241: 154-160.
Spindler J, Zandi S, Pfister IB, Gerhardt C & Garweg JG (2018): Cytokine profiles in the aqueous humor and serum of patients with dry and treated wet age-related macular degeneration. PLoS One 13: e0203337.
Sung HJ, Han JI, Lee JW, Uhm KB & Heo K (2012): TCCR/WSX-1 is a novel angiogenic factor in age-related macular degeneration. Mol Vis 18: 234-240.
Suzuki M, Tsujikawa M, Itabe H et al. (2012): Chronic photo-oxidative stress and subsequent MCP-1 activation as causative factors for age-related macular degeneration. J Cell Sci 125: 2407-2415.
Takahashi H, Tan X, Nomura Y et al. (2013): Associations between posterior vitreous detachment and concentrations of various cytokines in eyes with age-related macular degeneration and normal control eyes. Invest Ophthalmol Vis Sci 54: 4992.
Takahashi S, Adachi K, Suzuki Y, Maeno A & Nakazawa M (2016a): Profiles of inflammatory cytokines in the vitreous fluid from patients with rhegmatogenous retinal detachment and their correlations with clinical features. BioMed Res Int 2016: 4256183.
Takahashi H, Nomura Y, Nishida J et al. (2016b): Vascular Endothelial Growth Factor (VEGF) Concentration Is Underestimated by Enzyme-Linked Immunosorbent Assay in the Presence of Anti-VEGF Drugs. Invest Ophthalmol Vis Sci 57: 462-466.
Terao N, Koizumi H, Kojima K et al. (2018): Distinct Aqueous Humour Cytokine Profiles of Patients with Pachychoroid Neovasculopathy and Neovascular Age-related Macular Degeneration. Sci Rep 8: 10520.
Tong J-P, Chan W-M, Liu DTL, Lai TYY, Choy K-W, Pang C-P & Lam DSC (2006): Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 141: 456-462.
Tosi GM, Caldi E, Parolini B et al. (2017): CD93 as a potential target in neovascular age-related macular degeneration. J Cell Physiol 232: 1767-1773.
Tosi GM, Neri G, Caldi E et al. (2018a): TGF-β concentrations and activity are down-regulated in the aqueous humor of patients with neovascular age-related macular degeneration. Sci Rep 8: 8053.
Tosi GM, Orlandini M & Galvagni F (2018b): The Controversial role of TGF-β in neovascular age-related macular degeneration pathogenesis. Int J Mol Sci 19: 3363.
Wakshull E, Hong K, Day B, Bao M & Stoilov I (2018): Analysis of the serum and aqueous humor levels of IL-6 in patients with neovascular (wet) age-related macular degeneration (nAMD) receiving anti-vascular endothelial growth factor A monotherapy. Invest Ophthalmol Vis Sci 59: 1456.
Wang H & Hartnett ME (2016): Regulation of signaling events involved in the pathophysiology of neovascular AMD. Mol Vis 22: 189-202.
Warwick A & Lotery A (2018): Genetics and genetic testing for age-related macular degeneration. Eye (Lond) 32: 849-857.
Wei X, Balne PK, Au VB et al. (2018): Cytokine profiling in patients with exudative age-related macular degeneration due to choroidal neovascularization and polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci 59: 349.
Whiting PF, Rutjes AWS, Westwood ME et al. (2011): QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155: 529-536.
Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng C-Y & Wong TY (2014): Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2: e106-116.
Yi QY, Wang YY, Chen LS et al. (2019): Implication of inflammatory cytokines in the aqueous humour for management of macular diseases. Acta Ophthalmol 114: 2179-7.
Yuan J (2019): Role of inflammatory factors in the effects of aflibercept or ranibizumab treatment for alleviating wet age-associated macular degeneration. Exp Ther Med 17: 4249-4258.
Zandi S, Tappeiner C, Pfister IB et al. (2016): Vitreal cytokine profile differences between eyes with epiretinal membranes or macular holes. Invest Ophthalmol Vis Sci 57: 6320-6326.
Zapata MA, Carvalho AR, Figueras I et al. (2010): Profile of cytokines and pro-inflammatory mediators in aqueous humor and plasma of patients with high risk of progression age-related maculopathy. Invest Ophthalmol Vis Sci 51: 5902.
Zhao M, Bai Y, Xie W et al. (2015): Interleukin-1β level is increased in vitreous of patients with Neovascular Age-Related Macular Degeneration (nAMD) and Polypoidal Choroidal Vasculopathy (PCV). PLoS One 10: e0125150.
Zhou H, Zhao X, Yuan M & Chen Y (2020): Comparison of cytokine levels in the aqueous humor of polypoidal choroidal vasculopathy and neovascular age-related macular degeneration patients. BMC Ophthalmol 20: 15.
Zhu Q, Ziemssen F, Henke-Fahle S et al. (2008): Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology 115: 1750-1755.e1.